BPC 157: Experimental Peptide Creates Risk for Athletes BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Peptides are unproven as health aids. FDA may unleash them anyway